ONC Share Price Performance
CA$1.37
-0.02 (-1.44%)
Price CA$1.37
Share PriceCA$1.37
ONC Community Narratives
There are no narratives available yet.
Recent ONC News & Updates
No updates
Oncolytics Biotech Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.33
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Oncolytics Biotech Inc. Competitors
About ONC
- Founded
- 1998
- Employees
- 28
- CEO
- WebsiteView website
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Canadian Market Performance
- 7 Days: -1.4%
- 3 Months: 8.0%
- 1 Year: 18.6%
- Year to Date: 8.7%
Over the last 7 days, the market has dropped 1.7%, driven by a loss of 2.5% in the Financials sector. In contrast to the last week, the market is actually up 19% over the past year. Earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading